

**Table 1.** Clinical laboratory data and conventional risk factors of ischemic stroke patients and controls.

Parameter	Patients (n=256)	Controls (n=132)	P	OR(95%CI)
Age (years) <sup>a</sup>	65.5±13.4	64.4±12.2	0.096	
Male, n (%) <sup>b</sup>	144 (56.3)	64 (48.5)	0.163	1.366 (0.896-2.082)
Hypertension, n (%) <sup>b</sup>	173 (67.6)	51 (38.6)	<0.01	3.310 (2.138-5.216)
Diabetes mellitus, n (%) <sup>b</sup>	88 (34.4)	24 (18.2)	<0.01	2.357 (1.413-3.933)
Obesity, n (%) <sup>b</sup>	60 (23.4)	8 (6.1)	<0.01	4.745 (2.194-10.260)
Smokers, n (%) <sup>b</sup>	70 (27.3)	16 (12.1)	<0.01	2.728 (1.512-4.925)
Total cholesterol (mmol/L) <sup>c</sup>	4.8±1.3	4.7±1.3	0.268	
Triglycerides (mmol/L) <sup>c</sup>	1.6±0.7	1.5±0.7	0.277	
HDL-cholesterol (mmol/L) <sup>c</sup>	1.1±0.3	1.2±0.3	<0.01	
LDL-cholesterol (mmol/L) <sup>c</sup>	3.0±1.1	2.7±1.0	0.041	

Values are either number of subjects, percentage or mean ± SD.

<sup>a</sup>Mann Whitney U test is applied.

<sup>b</sup>Chi-square test is applied.

<sup>c</sup>Independent Samples T-test is applied.

**Table 2.** Distribution of CYP24A1 rs927650 and CYP2R1 rs10741657 genotypes and allele frequencies in ischemic stroke patients and controls.

	<b>Patients (n=256)</b>	<b>Controls (n=132)</b>	<b>OR (95%)</b>	<b>P</b>
<b>CYP24A1</b>				
<b>rs927650</b>				
<b>Genotypes, n%</b>				
CC	80 (31.3)	40 (30.3)		
CT	140 (54.7)	80 (60.6)	0.957 <sup>a</sup> (0.606-1.509)	0.848
TT	36 (14.0)	12 (9.1)		
Allele frequency				
C	0.586	0.606		
T	0.414	0.394	1.087 <sup>b</sup> (0.803-1.472)	0.589
<b>CYP2R1</b>				
<b>rs10741657</b>				
<b>Genotypes, n%</b>				
AA	33 (12.9)	22 (16.7)		
AG	108 (42.2)	49 (37.1)	1.352 <sup>c</sup> (0.752-2.428)	0.312
GG	115 (44.9)	61 (46.2)		
Allele frequency				
A	0.340	0.352	1.056 <sup>d</sup> (0.773-1.443)	0.720
G	0.660	0.648		

Note: Values are either number of subjects (n) or percentages. Comparisons are by Chi-square test.<sup>a</sup>CT+TT vs. CC, <sup>b</sup>C vs. T, <sup>c</sup>AG+GG vs. AA, <sup>d</sup>A vs. G.

**Table 3:** Stratification of hypertensive/normotensive, diabetic/non-diabetic, smoker/non-smoker and obese/non-obese individuals according to CYP24A1 rs927650 and CYP2R1 rs10741657 genotypes and ischemic stroke-control status.

Genotypes		Hypertensive	Normotensive	OR (95% CI)	P	Diabetic	Non-diabetic	OR (95% CI)	P
<b>CYP24A1</b>									
CC	stroke	55	25	3.667 (1.655-8.126)	<0.01	29	51	2.275 (0.926-5.588)	0.069
	control	15	25			8	32		
<b>CT+TT</b>	stroke	118	58	3.165 (1.875-5.342)	<0.01	59	117	2.395 (1.284-4.468)	<0.01
	control	36	56			16	76		
<b>CYP2R1</b>									
<b>AA</b>	stroke	18	15	2.571 (0.832-7.951)	0.097	9	24	1.000 (0.298-3.358)	1.000
	control	7	15			6	16		
<b>AG+GG</b>	stroke	155	68	3.419 (2.124-5.505)	<0.01	79	144	2.804 (1.578-4.982)	<0.01
	control	44	66			18	92		
		Smoker	Non-smoker	OR (95% CI)	P	Obese	Non-obese	OR (95% CI)	P
<b>CYP24A1</b>									
CC	stroke	15	65	1.308 (0.465-3.676)	0.610	9	71	4.944(0.604-40.476)	0.162 <sup>#</sup>
	control	6	34			1	39		
<b>CT+TT</b>	stroke	55	121	3.727 (1.797-7.733)	<0.01	51	125	4.138 (1.783-9.605)	<0.01
	control	10	82			7	85		
<b>CYP2R1</b>									
<b>AA</b>	stroke	12	21	12 (1.429-100.755)	<0.01 <sup>#</sup>	5	28	3.75 (0.407-34.539)	0.384 <sup>#</sup>
	control	1	21			1	21		
<b>AG+GG</b>	stroke	58	165	2.226 (1.196-4.144)	0.010	55	168	4.817 (2.113-10.98)	<0.01
	control	15	95			7	103		

Given values in the stroke and control lines are number of subjects (*n*).

Comparisons are by Chi-square test except for those marked with <sup>#</sup>for which Fisher's exact test was used.

**Table 4:** Logistic regression analysis of vascular risk factors (age, sex, hypertension, smoking status, diabetes and obesity), lipid parameters (total cholesterol, TG, LDL-cholesterol and HDL-cholesterol), CYP24A1 rs927650 and CYP2R1 rs10741657 genotypes in ischemic stroke patients and controls.

Parameters	OR	95% CI	P
Hypertension	3.387	2.095-5.475	<0.01
Smoking	3.074	1.598-5.915	<0.01
Obesity	2.730	1.211-6.155	0.015
HDL-cholesterol	0.276	0.119-0.640	<0.01
LDL-cholesterol	1.397	1.086-1.796	<0.01